晚期胰腺导管腺癌患者接受全身化疗时的白细胞介素-33 和可溶性肿瘤抑制物 2 的血浆水平。
Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy.
机构信息
Division of Oncology, Department of Medicine I, Comprehensive Cancer Center, Medical University Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Division of Cardiology, Department of Internal Medicine II, Medical University Vienna, Waehringer Guertel 18-20, Vienna, Austria.
出版信息
Med Oncol. 2018 Nov 13;36(1):1. doi: 10.1007/s12032-018-1223-3.
Interleukin-33 (IL-33) and its "decoy" receptor soluble ST2 (sST2) are involved in the development of chronic inflammation and cancer. We explored IL-33 and sST2 as a potential prognostic marker in patients with metastatic and locally advanced pancreatic ductal adenocarcinoma (PDAC). IL-33 and sST2 plasma levels were assessed in 20 patients with advanced PDAC before start of systemic chemotherapy and were analyzed in relation to clinical outcome. Kaplan Meier and multivariable Cox proportional hazards model analysis revealed a significant association between sST2 plasma levels and survival (HR 2.10, 95% CI 1.33-3.41, p = 0.002) and link high sST2 plasma levels to inferior survival in patients with advanced PDAC undergoing chemotherapy.
白细胞介素-33 (IL-33)及其“诱饵”受体可溶性 ST2 (sST2) 参与慢性炎症和癌症的发展。我们探讨了 IL-33 和 sST2 作为转移性和局部晚期胰腺导管腺癌 (PDAC) 患者的潜在预后标志物。在开始全身化疗前，评估了 20 例晚期 PDAC 患者的 IL-33 和 sST2 血浆水平，并分析了其与临床结果的关系。Kaplan-Meier 和多变量 Cox 比例风险模型分析显示，sST2 血浆水平与生存之间存在显著相关性 (HR 2.10，95% CI 1.33-3.41，p=0.002)，并且 sST2 血浆水平高与接受化疗的晚期 PDAC 患者的生存不良相关。
Zotero 插件